Raha Samraat S.
Raha Samraat S.'s purchase track record
Raha Samraat S. has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/9/2026 | MYGN | $200K | -8.7% | -33.9% | +12.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Agilent to acquire Proscia for up to $270M. Agilent Technologies has agreed to acquire digital pathology specialist Proscia in a deal valued at up to $270 million. The move is designed to strengthen Agilent's position in AI-enabled diagnostics and scientific intelligence. Following the announcement, TD Cowen raised its price target for the stock to $196.
Transaction History
| MYGN | ▲ Buy | Grant | 3,542 | $14K | 6/11/2026 | View on chart |
| MYGN | ▼ Sell | Tax Withholding | 10,816 | $50K | 3/14/2026 | View on chart |
| MYGN | ▼ Sell | Tax Withholding | 36,304 | $169K | 3/13/2026 | View on chart |
| MYGN | ▲ Buy | Grant | 618,557 | $0 | 3/12/2026 | View on chart |
| MYGN | ▲ Buy | Open Market | 40,000 | $200K | 3/9/2026 | View on chart |
| MYGN | ▼ Sell | Tax Withholding | 29,634 | $216K | 12/11/2025 | View on chart |
| MYGN | ▲ Buy | Grant | 1,498 | $5K | 5/31/2025 | View on chart |
| MYGN | ▼ Sell | Tax Withholding | 7,649 | $77K | 3/14/2025 | View on chart |
| MYGN | ▲ Buy | Grant | 216,495 | $0 | 3/13/2025 | View on chart |
| MYGN | ▼ Sell | Tax Withholding | 29,578 | $429K | 12/11/2024 | View on chart |
| MYGN | ▲ Buy | Grant | 1,118 | $15K | 11/30/2024 | View on chart |
| MYGN | ▲ Buy | Grant | 64,494 | $0 | 3/14/2024 | View on chart |
| MYGN | ▲ Buy | Grant | 236,360 | $0 | 12/11/2023 | View on chart |
| A | ▼ Sell | Tax Withholding | 1,578 | $179K | 11/17/2023 | View on chart |
| A | ▼ Sell | Tax Withholding | 345 | $39K | 11/16/2023 | View on chart |
| A | ▼ Sell | Tax Withholding | 428 | $49K | 11/15/2023 | View on chart |
| A | ▲ Buy | Grant | 11,225 | $1.3M | 11/14/2023 | View on chart |
| A | ▼ Sell | Tax Withholding | 3,171 | $354K | 11/14/2023 | View on chart |
| A | ▼ Sell | Tax Withholding | 1,120 | $164K | 11/18/2022 | View on chart |
| A | ▼ Sell | Tax Withholding | 457 | $66K | 11/17/2022 | View on chart |
| A | ▼ Sell | Tax Withholding | 344 | $51K | 11/16/2022 | View on chart |
| A | ▲ Buy | Grant | 3,453 | $511K | 11/15/2022 | View on chart |
| A | ▲ Buy | Grant | 20,566 | $3.0M | 11/15/2022 | View on chart |
| A | ▼ Sell | Tax Withholding | 7,646 | $1.1M | 11/15/2022 | View on chart |
| A | ▼ Sell | Tax Withholding | 737 | $109K | 11/11/2022 | View on chart |
| A | ▼ Sell | Tax Withholding | 226 | $27K | 5/13/2022 | View on chart |
| A | ▼ Sell | Tax Withholding | 1,121 | $184K | 11/19/2021 | View on chart |
| A | ▼ Sell | Tax Withholding | 457 | $74K | 11/17/2021 | View on chart |
| A | ▲ Buy | Grant | 17,869 | $2.9M | 11/16/2021 | View on chart |
| A | ▼ Sell | Tax Withholding | 8,696 | $1.4M | 11/16/2021 | View on chart |
| A | ▲ Buy | Grant | 2,774 | $448K | 11/16/2021 | View on chart |
| A | ▼ Sell | Tax Withholding | 737 | $119K | 11/12/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Myriad Genetics Faces Risk Concerns Highlighted in Recent Analysis
An analysis on Yahoo points out three major risks for Myriad Genetics, raising questions about the company's future prospects. The stock is trading near its 14‑touch support level of $4.55 and sits above the 52‑week low of $2.74. Analysts average a target of $3.37, with a range from $2.00 to $5.00, suggesting a cautious view. The broader diagnostics market is also seeing growth, which may influence Myriad’s competitive environment.
Myriad Genetics Faces Risk Concerns Highlighted in Recent Analysis. An analysis on Yahoo points out three major risks for Myriad Genetics, raising questions about the company's future prospects. The stock is trading near its 14‑touch support level of $4.55 and sits above the 52‑week low of $2.74. Analysts average a target of $3.37, with a range from $2.00 to $5.00, suggesting a cautious view. The broader diagnostics market is also seeing growth, which may influence Myriad’s competitive environment.